Company intelligence / Profile preview
Triphase Research and Development
San Diego, California, United Statestriphaserd.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
TRPH‑222, an antibody-drug conjugate targeting CD22, has completed a Phase I multicenter open-label study in relapsed/refractory B-cell lymphoma. The company’s pipeline also includes small molecule drugs targeting proteasome and WDR5 with preclinical or pending status in solid tumors and AML.
- Therapeutic areas
- Oncology
- Modalities
- Antibody-drug conjugates (ADC)Small molecule drugs
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Celgene Corporation has been a collaborator/sponsor on clinical trials.
Beyond the preview
Go deeper on Triphase Research and Development.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Triphase Research and Development.